SCHEDULE: Wellington Management Discloses 2.8% Stake in Xenon

Wellington Management Group and its affiliates have disclosed a 2.8% passive ownership stake in Xenon Pharmaceuticals Inc. as of June 30, 2025.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively reported beneficial ownership of 2,174,761 shares of Xenon Pharmaceuticals Inc. common stock.
• This represents 2.8% of the total class of securities.
• The reporting persons hold shared voting power over 2,146,462 shares and shared dispositive power over 2,174,761 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Xenon Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: This is a routine disclosure of a passive ownership stake by an institutional investor, providing no new operational or financial information about the issuer.

Positives

• A significant institutional investor, Wellington Management Group, holds a stake in Xenon Pharmaceuticals Inc., indicating their investment interest.

Future Outlook

No forward-looking statements or guidance regarding Xenon Pharmaceuticals Inc.'s business operations or financial performance are provided.

Management Comments

• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates continued institutional interest in the pharmaceutical and biotechnology sector, specifically in Xenon Pharmaceuticals. It represents a routine disclosure for large passive stakes held by asset management firms.

Comparison to Industry Standards

• The 2.8% ownership stake is below the 5% threshold that would typically necessitate a Schedule 13D filing, reinforcing its passive investment nature.
• Wellington Management Group's filing as a passive investor is consistent with its role as a large asset manager, which routinely discloses such stakes.
• This type of disclosure is standard practice for institutional investors managing diversified portfolios, aligning with global regulatory transparency requirements for significant shareholdings.

Stakeholder Impact

• Shareholders: Provides transparency on institutional ownership, potentially signaling investor confidence.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a passive ownership stake by Wellington Management Group and its affiliates in Xenon Pharmaceuticals Inc. It does not contain new operational, financial, or strategic information about Xenon Pharmaceuticals Inc. that would warrant a change in investment recommendation. The stake is below the 5% threshold for active influence, indicating a routine portfolio holding.

Keywords

Xenon Pharmaceuticals, XENE, Wellington Management, Schedule 13G, Institutional Ownership, Common Stock, Pharmaceutical, Biotechnology